Global Respiratory Drugs Market Research to Expands at 6.48% CAGR from 2016 to 2020 Stimulated by Rising Environmental Pollution has announced the addition of a report, titled “Global Respiratory Drugs Market 2016-2020,” to its database.


Albany, NY -- (SBWIRE) -- 11/18/2016 -- The detailed report contains data about the current state of the global respiratory drugs market as well as the future predictions. It studies the growth opportunities and the obstacles faced by the market. According to the report, the global respiratory drugs market is expected to expand at a 6.48% CAGR between 2016 and 2020 owing to the rising incidences of respiratory disorders among people.

View Full Report:

Respiratory diseases are becoming increasingly common among people across the world. Asthma, allergic rhinitis, cystic fibrosis, COPD, pulmonary hypertension, and IPF are some of the respiratory disorders affecting people. Due to extensive environmental pollution, there is a rise in the prevalence of respiratory diseases. Changing lifestyles and hereditary issues are also factors that lead to respiratory disorders. Occupational and environmental lung disease is also a cause for respiratory disorders, which are caused among people working in environments with dust, chemicals, and other irritants.

COPD is a disease which includes either one or a combination of two breathing disorders – chronic bronchitis and emphysema. COPD causes symptoms such as breathlessness, chronic cough, chest tightness, and wheezing.

Asthma is a disease associated with inflammation of the bronchial tubes. The inflamed or swollen bronchial tubes become sensitive to various allergen, causing the tubes to become narrower, making it even more difficult to breathe. Less airflow in the lungs causes wheezing, chest tightness, and cough, especially at night and early morning.

For Sample Copy, click here:

In order to treat respiratory disorders several medicines are used. These include antihistamines, bronchodilators, immunosuppressants, leukotriene antagonists, and intranasal corticosteroids. The choice of medicines prescribed depends on the type of disorder. The global respiratory drugs market is segmented on the basis of geography into the Americas, Asia Pacific, and Europe, the Middle East and Africa.

The report is an in-depth market analysis with inputs from experts from the industry. Growth factors, opportunities, and the future scope of the market have been discussed. The report also studies major players operating in the respiratory drugs market. The study of major players helps interested readers and enterprises to invest in the market by making smart decisions. The business overview, financial overview, product specification, contact information, and most importantly, the strategies implemented by the key players have been presented. All information is given in a clear and concise manner enabling an enhanced reading experience. Graphs, charts, tables, and statistics have been included wherever required.

Some of the major players discussed in the report are: AstraZeneca, Boehringer Ingelheim, ImmuneWorks, Abbott, Actavis, Alere, Orchid Chemicals and Pharmaceuticals, Pfizer, Almirall, Amgen AptarGroup, Astellas, Aurobindo, Baxter, Bayer, Biogen, Biotest, Bristol-Myers Squibb, Shionogi, Chiesi Farmaceutici, Cipla, Cytos, Dr. Reddy's Laboratories, FibroGen, Gilead Sciences, Glenmark, GNI Group Ltd, Horizon Pharma, Perrigo, Promedior, Prometheus, ProMetic Life Sciences, Ranbaxy, Sanofi, Siemens Healthcare Diagnostics, Sunovion, Teva Theravance, Vertex, Zai Lab, GlaxoSmithKline, Merck, and Novartis.

To order report Call Toll Free: 866-997-4948 or send an email on